Allergy's birch pollen vaccine misses in Phase III

Allergy Therapeutics said Pollinex Quattro Birch missed the primary endpoint in the Phase III B301 trial to treat birch pollen-induced seasonal allergic rhinitis.

Pollinex Quattro Birch failed to significantly improve the total combined symptom medication score (CSMS) of the rhinoconjunctivitis daily symptom score and rhinoconjunctivitis daily medication score averaged over the peak birch pollen season vs. placebo...